UroGen Pharma Ltd. Amortization of Debt Discount (Premium)
UroGen Pharma Ltd. (URGN) reported Amortization of Debt Discount (Premium) of $1.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-05
- UroGen Pharma Ltd. amortization of debt discount (premium) for the quarter ending 2026-06-30 was -$796.00K, a 299.00% decline year-over-year.
- UroGen Pharma Ltd. amortization of debt discount (premium) for the quarter ending 2026-03-31 was $1.97M, a 427.81% increase year-over-year.
- UroGen Pharma Ltd. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $99.00K, a 296.00% increase year-over-year.
- UroGen Pharma Ltd. amortization of debt discount (premium) for the quarter ending 2025-09-30 was -$397.00K.
- UroGen Pharma Ltd. amortization of debt discount (premium) for fiscal 2025 was $476.00K.
- UroGen Pharma Ltd. amortization of debt discount (premium) for fiscal 2024 was -$1.30M, a 228.70% decline from fiscal 2023.
- UroGen Pharma Ltd. amortization of debt discount (premium) for fiscal 2023 was $1.01M, a 42.19% decline from fiscal 2022.
- UroGen Pharma Ltd. amortization of debt discount (premium) for fiscal 2022 was $1.75M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$796.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.18M 10-Q · filed 2026-08-05 | $1.28M derived: sum of 3 quarters · filed 2026-08-05 | $880.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.97M 10-Q · filed 2026-05-06 | $2.07M derived: sum of 2 quarters · filed 2026-05-06 | $1.68M derived: sum of 3 quarters · filed 2026-05-06 | $2.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$298.00K derived: sum of 2 quarters · filed 2026-03-02 | $102.00K derived: sum of 3 quarters · filed 2026-08-05 | $476.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | -$397.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.00K derived: sum of 2 quarters · filed 2026-08-05 | $377.00K 10-Q · filed 2025-11-06 | $402.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $774.00K 10-Q · filed 2026-08-05 | $799.00K derived: sum of 3 quarters · filed 2026-08-05 | $207.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $374.00K 10-Q · filed 2026-05-06 | $399.00K derived: sum of 2 quarters · filed 2026-05-06 | -$193.00K derived: sum of 3 quarters · filed 2026-05-06 | $30.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$567.00K derived: sum of 2 quarters · filed 2026-03-02 | -$344.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.30M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$592.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$369.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.33M 10-Q · filed 2025-11-06 | -$1.30M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$738.00K 10-Q · filed 2025-08-07 | -$705.00K derived: sum of 3 quarters · filed 2025-08-07 | -$483.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$961.00K 10-Q · filed 2025-05-12 | -$928.00K derived: sum of 2 quarters · filed 2025-05-12 | -$706.00K derived: sum of 3 quarters · filed 2025-05-12 | -$351.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $255.00K derived: sum of 2 quarters · filed 2025-03-10 | $610.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.01M 10-K · filed 2025-03-10 |
| 2023-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $577.00K derived: sum of 2 quarters · filed 2024-11-06 | $981.00K 10-Q · filed 2024-11-06 | $1.66M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $355.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $759.00K 10-Q · filed 2024-08-13 | $1.44M derived: sum of 3 quarters · filed 2024-08-13 | $2.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $404.00K 10-Q · filed 2024-05-13 | $1.08M derived: sum of 2 quarters · filed 2024-05-13 | $1.75M derived: sum of 3 quarters · filed 2024-05-13 | $1.88M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.35M derived: sum of 2 quarters · filed 2024-03-14 | $1.47M derived: sum of 3 quarters · filed 2024-03-14 | $1.75M 10-K · filed 2024-03-14 |
| 2022-09-30 | $674.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $795.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.08M 10-Q · filed 2023-11-14 | $1.08M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $403.00K 10-Q · filed 2023-08-10 | $403.00K derived: sum of 3 quarters · filed 2023-08-10 | |
| 2022-03-31 | $282.00K 10-Q · filed 2023-05-11 | $282.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |